Clinical Trials - August 26, 2019
Spago Nanomedical initiates new clinical trial
The company has conducted site initiation visit at the Uppsala University Hospital in Uppsala and formally opened the first clinical trial with the tumor selective contrast agent SpagoPix (SN123D). The trial will include up to 20 patients with confirmed breast cancer. The primary objective with the trial is to document safety, but another important objective […]
Intellectual Property - August 13, 2019
Spago Nanomedical receives patent approval
The European Patent Office (EPO) has approved the company’s patent application concerning the nanoparticles behind the SpagoPix project. “A strong patent is valuable both for us and for future potential partners. SpagoPix will have exclusivity during many years on the three most important markets; USA, Europe and Japan,” says Mats Hansen, CEO of Spago Nanomedical. […]
Business article - June 13, 2019
Interview: Spago Nanomedical – Aiming to improve cancer care
The company recently reached an important milestone with its contrast agent SpagoPix and, if the results are positive, it could enhance cancer care. Spago Nanomedical was founded in 2007 as a subsidiary of Accelerator Nordic. The purpose was to advance an invention from the University of Linköping regarding the use of gadolinium-based nanoparticles as a […]
Clinical Trials - February 23, 2017
Promising results for Spago Nanomedical
Collective data from recently completed toxicity studies show that the product candidate SN132D can be given safely at doses that widely exceeds the expected clinical dose. At the end of 2016, Spago Nanomedical formally announced its product candidate in the SpagoPix project. The product candidate, designated SN132D, has now been investigated in several preclinical pilot […]
